Tofacitinib Market Report 2026

The tofacitinib market size has grown rapidly in recent years. It will grow from $3.42 billion in 2025 to $3.86 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to rising cases of rheumatoid arthritis, increasing awareness of ulcerative colitis, expansion of biologics market, approval of janus kinase inhibitors, growth of hospital pharmacy networks.

The tofacitinib market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to development of novel tofacitinib formulations, growing focus on precision medicine, increasing investment in biosimilars, expansion of online pharmacy channels, rising demand for immunosuppressants. Major trends in the forecast period include increasing adoption of targeted therapies, rising prevalence of ulcerative colitis and rheumatic diseases, shift towards personalized medicine, growing biopharmaceutical r&d investments, expansion of specialty pharmacies.

The rising number of patients with inflammatory bowel disease (IBD) is expected to drive the growth of the tofacitinib market in the coming years. IBD is a group of chronic inflammatory disorders of the gastrointestinal tract, primarily including Crohn’s disease and ulcerative colitis. Tofacitinib is used to manage IBD by inhibiting Janus kinase (JAK) enzymes, reducing symptoms, and promoting mucosal healing. For example, in June 2023, Crohn’s and Colitis Canada, a non-profit organization, estimated that over 322,600 Canadians were living with IBD, representing approximately 0.82% of the population. The prevalence is projected to rise, with around 470,000 Canadians expected to have IBD by 2035, accounting for roughly 1.1% of the population, or 1 in every 91 individuals. Consequently, the increasing prevalence of IBD is fueling the growth of the tofacitinib market.

Leading companies in the tofacitinib market are focusing on developing topical formulations to gain a competitive advantage. Topical tofacitinib is designed for application directly to the skin. For instance, in June 2023, Intas Pharmaceuticals, an India-based pharmaceutical company, launched Tofacitinib Topical (JAKi) for treating mild to moderate atopic dermatitis (AD) in India. This marked the first JAK inhibitor approved for AD in the country. A Phase III clinical study of TOFATAS (Tofacitinib Ointment 2% w/w) in Indian AD patients demonstrated significant safety and efficacy. The launch of TOFATAS provides a new treatment option for AD patients, as no topical JAK inhibitors were previously approved in India.

In January 2025, Fiocruz, a Brazil-based public health institution specializing in research, development, and production of vaccines and medicines, partnered with Pfizer Inc. to produce a generic version of Xeljanz (Tofacitinib) in Brazil. This collaboration aims to expand local access to advanced rheumatoid arthritis therapies while allowing Pfizer to strengthen its presence and improve patient access in the country. Pfizer Inc. is a US-based manufacturer of tofacitinib.

Major companies operating in the tofacitinib market are Pfizer Inc, Beacon Pharmaceuticals Limited, Glenmark Pharmaceuticals LTD, Sun Pharmaceutical Industries Ltd, Zydus Lifesciences Ltd, Unichem Laboratories, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd, Lupin Limited, Aurobindo Pharma Limited, Cipla Inc, Dr. Reddys Laboratories Ltd, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited.

North America was the largest region in the tofacitinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tofacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the tofacitinib market by affecting the import and export of active pharmaceutical ingredients (APIs) and raw materials, leading to increased production costs. The impact is most pronounced in regions such as Asia-Pacific and Europe, where major manufacturing and supply chain hubs exist, particularly for hospital and retail pharmacy segments. While tariffs may slow the entry of lower-cost alternatives, they also encourage local production and innovation, creating opportunities for domestic manufacturers to strengthen their market presence and improve supply chain resilience.

The tofacitinib market research report is one of a series of new reports that provides tofacitinib market statistics, including tofacitinib industry global market size, regional shares, competitors with a tofacitinib market share, detailed tofacitinib market segments, market trends and opportunities, and any further data you may need to thrive in the tofacitinib industry. This tofacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tofacitinib is a medication used to treat ulcerative colitis and other rheumatic conditions, including rheumatoid arthritis and ankylosing spondylitis. It is prescribed for moderate to severely active ulcerative colitis in patients who are intolerant of, respond poorly to, or lose response to biological therapy or conventional treatments.

The main drug classes of tofacitinib include antirheumatic, Janus kinase inhibitor, and immunosuppressant. Antirheumatic drugs are medications used to manage rheumatism. Available strengths include 5 mg, 10 mg, 11 mg, and 22 mg, administered orally and via other routes. Tofacitinib is distributed through hospital pharmacies, retail pharmacies, and online pharmacies for conditions such as ulcerative colitis, rheumatoid arthritis, psoriasis, and other related diseases.

The tofacitinib market consists of sales of Xeljanz and Xeljanz XR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.